Eyebright Medical Technology (Beijing) Co., Ltd.: history, ownership, mission, how it works & makes money

Founded on April 21, 2010 and listed on the Shanghai Stock Exchange under 688050, Eyebright Medical Technology has grown into a vertically integrated ophthalmic device group with production bases across Yantai, Suzhou, Hangzhou, Lianyungang, Chengdu, Fuzhou, Hong Kong and Switzerland and a workforce that is 57% female and 43% male; the company reported 1.41 billion CNY in revenue for 2024 (a 48.24% year‑over‑year increase) and a net profit attributable to shareholders of 388.40 million CNY (up 27.77%), while as of December 12, 2025 its market capitalization stood at about 11.81 billion CNY with 193.40 million shares outstanding and a July 2025 dividend of 0.35 CNY per share; strategic moves include a 175 million CNY investment for a 36.84% stake in Fujian Unicon (July 2023) and a 51% joint venture with Hong Kong Unicon (May 2024), certification milestones such as the Class III approval for the self‑developed Loong Crystal™ PR phakic IOL in January 2025 and ISO 14001, 50001, and 45001 certifications in March-February-March 2025, plus sustainability measures (photovoltaic systems, water‑saving recognition), targeted R&D and training bases (China Eye Valley, Tianjin Eye Hospital Vision Center, Beijing HQ), share buybacks of 20.04 million CNY and executive buy‑ins of 3.44 million CNY, all underpinning its product mix of intraocular lenses, orthokeratology lenses and soft contact lenses and ongoing internationalization via a Hong Kong office established in 2023.

Eyebright Medical Technology Co., Ltd. (688050.SS): Intro

• Founded: April 21, 2010 (Beijing)
• Shanghai Stock Exchange listing: 2010 - ticker 688050
• Core focus: ophthalmic implants, intraocular lenses (IOLs), phakic IOLs, and related surgical consumables

• 2010-2014: Founding and early product development focused on topical ophthalmic devices and basic IOL prototypes.
• 2015-2019: Expanded R&D and manufacturing capacity; pursued domestic clinical pathways and hospital partnerships.
• 2020-2024: Increased emphasis on higher-value intraocular implants and regulatory groundwork for advanced phakic IOLs.
• 2025: Achieved multiple ISO certifications (50001, 14001, 45001) and NMPA Class III approval for Loong Crystal™ PR, signaling maturation into premium intraocular device markets.

• Listed company on Shanghai exchange under code 688050 - publicly traded with institutional and retail investors.
• Typical ownership slices for comparable Chinese medtechs: institutional investors, management/founders, and float - company-disclosed breakdown should be checked in its latest shareholder registry for precise percentages.
• Subsidiaries and manufacturing arms are organized under the Beijing holding entity to centralize R&D, regulatory affairs and production management.

• Mission: Develop safe, high-performance ophthalmic implants and devices to improve vision outcomes.
• Strategic priorities: clinical differentiation (premium phakic IOLs), regulatory leadership, manufacturing quality, and sustainability/energy management (evidenced by ISO certifications).
• For an expanded company mission and values overview see: Mission Statement, Vision, & Core Values (2026) of Eyebright Medical Technology (Beijing) Co., Ltd.

• Core products: intraocular lenses (including aspheric phakic IOLs), implantable optics, and surgical consumables designed for refractive correction and cataract-related indications.
• R&D model: internal design, preclinical testing, clinical trials for NMPA filings, and iterative product refinement informed by surgeon feedback.
• Manufacturing: controlled cleanroom production of polymer/biocompatible optics, precision machining, inspection and sterilization processes aligned with medical device GMP.
• Regulatory pathway: devices categorized per NMPA rules (Class II/III) with necessary clinical data packages; recent Class III approval for Loong Crystal™ PR demonstrates capability to navigate high‑barrier approvals.

• Product sales: primary revenue from sale of IOLs and related consumables to hospitals, surgical centers and distributors.
• Channel model: direct hospital contracts, distributor partnerships, and tenders for public procurement in China.
• Value capture: higher-margin premium implants (e.g., patented aspheric phakic IOLs) and after-sales services (training, warranties, surgical support).
• R&D-driven pipeline: new approvals expand addressable market and allow price premia vs commodity lenses.

• Regulatory capability: Class III NMPA approval is a strategic moat for implantable devices.
• Quality and standards: ISO 50001/14001/45001 certifications indicate systematic management of energy, environment and occupational safety - factors that reduce operational risk and support tender eligibility.
• Surgeon adoption: sales growth depends on clinician training, clinical evidence (outcomes, complication rates), and reimbursement/pricing dynamics in China.

Eyebright Medical Technology Co., Ltd. (688050.SS): History

• Listing: Traded on SSE under stock code 688050.
• Shares outstanding: 193.40 million shares.
• Market capitalization (as of 12 Dec 2025): ≈ 11.81 billion CNY.
• Dividend policy: Declared a cash dividend of 0.35 CNY per share in July 2025.

• July 2023: Invested 175 million CNY to acquire a 36.84% equity interest in Fujian Unicon, strengthening presence in the contact-lens market.
• May 2024: Entered a joint venture with Hong Kong Unicon Optical Co., Limited, holding a 51% stake focused on R&D, manufacturing, and sales of soft contact lenses and optometric products in China.

Eyebright Medical Technology Co., Ltd. (688050.SS): Ownership Structure

• Mission: develop safe, effective ophthalmic medical devices and deliver scalable clinical solutions to improve eye health worldwide.
• Environmental commitment: ISO 14001 and ISO 50001 certified for environmental management and energy efficiency.
• Social responsibility: listed in Beijing's directory of water‑saving enterprises for water‑saving innovations and efficient resource utilization.
• Corporate governance: achieved an A‑level disclosure rating from the Shanghai Stock Exchange for two consecutive years.
• Workforce and talent development: structured training and career progression programs; workforce composition is 57% female and 43% male.
• Occupational health & safety: ISO 45001 certified, reflecting formalized OHS management systems.

• How it works: R&D drives new ophthalmic device development (diagnostics, surgical instruments, disposables), followed by regulatory approvals, clinical partnerships, and distribution across hospitals, ophthalmic clinics and specialty channels.
• How it makes money: product sales (hospital tenders, direct supply to clinics), after‑sales services, consumables and recurring disposables, plus potential licensing or OEM arrangements.

Eyebright Medical Technology Co., Ltd. (688050.SS): Mission and Values

• Vertical integration: in-house research, design, production, sterilization and commercialization-reducing time-to-market and protecting IP.
• Product lifecycle coverage: devices across diagnosis, surgical correction and vision correction lenses to serve patients from myopia control to cataract and refractive surgery.
• Clinical and training network: company-run training centers and hospital partnerships to accelerate clinical adoption and post-market feedback loops.

• Production and R&D bases located in: Yantai, Suzhou, Hangzhou, Lianyungang, Chengdu, Fuzhou, Hong Kong and Switzerland (8 sites) to support localized manufacturing and international distribution.
• Training bases established at China Eye Valley, Tianjin Eye Hospital Vision Center and Beijing headquarters to train surgeons, optometrists and sales/technical staff.
• Energy and sustainability: installation of photovoltaic systems at selected production facilities to lower grid electricity consumption and operating carbon intensity.

• Core product lines:
  • Intraocular lenses (IOLs), including phakic and cataract IOLs
  • Orthokeratology (OK) rigid gas-permeable lenses for myopia control
  • Soft contact lenses for daily and extended wear
• Flagship innovations: Loong Crystal™ PR phakic intraocular lens - proprietary design targeted at high myopia patients seeking reversible refractive correction.
• R&D model: iterative clinical feedback from training centers and hospital partners used to refine optics, materials and delivery systems.

• Direct sales to hospitals and clinics plus authorized distributors for regional reach.
• Services and training monetization: paid surgeon training programs, surgical consumables and clinical support contracts.
• Recurring consumable revenue from contact lens replacement cycles and after-sales clinical supplies.

• Training curriculum targets: refractive surgeons, ophthalmic technicians and optometrists to drive safe adoption and capture clinical outcome data.
• Hands-on and classroom modules delivered at company training bases and partner hospitals to shorten learning curves for new implants and techniques.

• Control of manufacturing and quality across the full device lifecycle improves margin potential and regulatory compliance.
• Close integration of R&D, clinical training and sales accelerates iterative product improvement and market penetration.
• Global footprint (including Switzerland) supports export and alignment with international regulatory pathways.

Eyebright Medical Technology Co., Ltd. (688050.SS): How It Works

• Core product lines: intraocular lenses (IOLs) for cataract surgery, orthokeratology (OK) rigid gas-permeable lenses for myopia control, and soft contact lenses for daily and specialty use.
• Revenue model: direct sales to hospitals and clinics, distribution partnerships, e-commerce channels for consumer lenses, OEM/ODM manufacturing contracts, and licensing/R&D collaborations.
• Value chain activities: internal R&D and clinical trials, precision manufacturing, regulatory approval (CFDA/NMPA and overseas equivalents), clinical training for surgeons, and after-sales clinical support.

• How products generate cash:
  • IOLs: hospital procurement cycles and higher ASPs per implanted device drive recurring institutional revenue.
  • OK lenses: subscription-style replacement cadence and fittings create steady unit sales plus clinic referral income.
  • Soft contact lenses: higher-volume, lower-margin consumer sales balanced by branded and OEM channels.
• Profit drivers: scaling manufacturing yields, mix-shift toward higher-margin surgical products, R&D-driven premium offerings, and operational efficiencies reflected in a 27.77% rise in net profit in 2024.
• Capital allocation to shareholder value: 20.04 million CNY share buybacks and 3.44 million CNY in executive buy-ins signal alignment with minority holders and confidence in internal cash generation.
• Portfolio diversification: a 36.84% stake in Fujian Unicon expands exposure to the contact lens segment and creates cross-selling and manufacturing synergies.
• International expansion: the 2023 Hong Kong office provides a base for global business development, investor relations and potential fundraising to support overseas market entry.

Eyebright Medical Technology Co., Ltd. (688050.SS): How It Makes Money

• Primary revenue from sales of ophthalmic implants and surgical instruments, led by the Loong Crystal™ PR phakic intraocular lens.
• Recurring revenue from consumables and after‑sales services (surgical support, training, maintenance).
• Licensing, OEM/co‑development agreements and income from joint ventures that commercialize niche ophthalmic technologies.
• International sales growth via its Hong Kong office and collaborations (including Invest Hong Kong) to access APAC and global markets.

• Diversified income mix reduces single‑product risk: implants, consumables, services, licensing, JV proceeds.
• R&D pipeline and IP (e.g., Loong Crystal™ PR) aim to sustain pricing power and ASPs (average selling prices) in premium segments.
• Internationalization and partnerships target margin expansion by entering higher‑value markets and securing reimbursement pathways.